2020
Intestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction
Vyas M, Celli R, Singh M, Patel N, Aslanian HR, Boffa D, Deng Y, Ciarleglio MM, Laine L, Jain D. Intestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction. Human Pathology 2020, 105: 67-73. PMID: 32941964, PMCID: PMC11152084, DOI: 10.1016/j.humpath.2020.08.007.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsBile refluxIntestinal metaplasiaReactive gastropathyGEJ regionMucosal injuryMucosal changesGastroesophageal junctionAntral intestinal metaplasiaDistal esophageal adenocarcinomaDetailed clinical historySex-matched patientsGastric antral biopsiesAnti-inflammatory drugsGastric bile refluxMucosal inflammationProximal stomachDistal esophagusMedication usePancreatic metaplasiaPathology databaseProximal gastricAntral biopsiesClinical historyGastric biopsies
2012
Management of Patients With Ulcer Bleeding
Laine L, Jensen DM. Management of Patients With Ulcer Bleeding. The American Journal Of Gastroenterology 2012, 107: 345. PMID: 22310222, DOI: 10.1038/ajg.2011.480.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBlood TransfusionClinical Trials as TopicEndoscopy, GastrointestinalErythromycinEvidence-Based MedicineFluid TherapyGastric LavageHemostasis, EndoscopicHumansMeta-Analysis as TopicPatient SelectionPeptic Ulcer HemorrhagePrognosisProton Pump InhibitorsResuscitationRetreatmentRisk AssessmentSecondary PreventionConceptsNonsteroidal anti-inflammatory drugsAnti-ulcer therapyEndoscopic therapyHemodynamic statusCOX-2-selective nonsteroidal anti-inflammatory drugsNon-bleeding visible vesselOvert upper gastrointestinal bleedingDirect further managementSecond endoscopic treatmentStep-wise managementUpper gastrointestinal bleedingManagement of patientsProton pump inhibitorsAnti-inflammatory drugsIdiopathic ulcersPPI therapyActive bleedingGastrointestinal bleedingRecurrent bleedingUlcer bleedingEndoscopic featuresFirst endoscopyUpper endoscopyAdherent clotEndoscopic treatment
2010
Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients. Alimentary Pharmacology & Therapeutics 2010, 32: 1240-1248. PMID: 20955443, DOI: 10.1111/j.1365-2036.2010.04465.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalArthritisCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibFemaleGastrointestinal DiseasesHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesPyridinesRisk FactorsSulfonesTime FactorsUpper Gastrointestinal TractConceptsClinical eventsRisk factorsLow-dose aspirin useDouble-blind randomized trialsLong-term prospective studiesCox proportional hazards modelNonsteroidal anti-inflammatory drugsDiscontinuation of NSAIDsPredictors of discontinuationUpper GI eventsLow-dose aspirinPotential risk factorsProportional hazards modelAnti-inflammatory drugsAspirin useGI eventsPatient characteristicsArthritis patientsTreat analysisRandomized trialsRheumatoid arthritisProspective studyGI effectsDyspepsiaHazards model
2008
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. The American Journal Of Gastroenterology 2008, 103: ajg2008576. PMID: 18853980, DOI: 10.1111/j.1572-0241.2008.02200.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonselective nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsGI risk factorsNonsteroidal anti-inflammatory drugsCV riskHigh CV riskProton pump inhibitorsAnti-inflammatory drugsRisk factorsCyclooxygenase-2- selective nonsteroidal antiinflammatory drugsSelective nonsteroidal antiinflammatory drugsCardiovascular safety issuesMultidisciplinary international panelPatient's CV riskClinical practice recommendationsManagement of patientsAnti-platelet agentsGI complicationsCardiovascular effectsGI riskInternational working partyPump inhibitorsTreatment strategiesAntiinflammatory drugsPatientsGastric Mucosal Defense and Cytoprotection: Bench to Bedside
Laine L, Takeuchi K, Tarnawski A. Gastric Mucosal Defense and Cytoprotection: Bench to Bedside. Gastroenterology 2008, 135: 41-60. PMID: 18549814, DOI: 10.1053/j.gastro.2008.05.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsStress-related mucosal diseaseProton pump inhibitorsMucosal defenseGastric mucosal defenseMucosal injuryNoxious factorsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsGeneration of PGsImportant clinical sequelaeUpper gastrointestinal complicationsHigh-risk patientsModern intensive careAbsolute risk reductionInhibition of cyclooxygenaseAnti-inflammatory drugsContinuous blood flowGastrointestinal complicationsClinical sequelaePharmacologic therapyAntisecretory drugsSignificant bleedingAnnual incidenceIntensive careSensory innervation
2006
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
Cannon CP, Curtis SP, Bolognese JA, Laine L, Committee F. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. American Heart Journal 2006, 152: 237-245. PMID: 16875903, DOI: 10.1016/j.ahj.2006.05.024.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidAspirinCyclooxygenase InhibitorsDiclofenacDouble-Blind MethodEtoricoxibFemaleHumansMaleMiddle AgedMulticenter Studies as TopicOsteoarthritisPatient SelectionPyridinesRandomized Controlled Trials as TopicResearch DesignRisk AssessmentSulfonesTreatment OutcomeConceptsNonsteroidal anti-inflammatory drugsAnnual event rateThrombotic cardiovascular eventsRheumatoid arthritisCardiovascular eventsEvent ratesHazard ratioTraditional nonsteroidal anti-inflammatory drugsCyclooxygenase-2 selective inhibitorCOX-2 selective inhibitorsTraditional NSAID diclofenacDouble-blind trialCardiovascular event ratesTreatment of patientsAnti-inflammatory drugsClinical trial designSelective inhibitorLong-term useMultinational EtoricoxibCardiovascular outcomesCardiovascular riskPatient demographicsNoninferiority criteriaControl armCOX-2GI Risk and Risk Factors of NSAIDs
Laine L. GI Risk and Risk Factors of NSAIDs. Journal Of Cardiovascular Pharmacology 2006, 47: s60-s66. PMID: 16785831, DOI: 10.1097/00005344-200605001-00011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI eventsClinical eventsNSAID useGI eventsRisk factorsMultiple nonsteroidal anti-inflammatory drugsNon-NSAID analgesicsUpper GI symptomsUse of coxibsUpper gastrointestinal complicationsUse of corticosteroidsRegular NSAID useImportant risk factorLowest effective doseAnti-inflammatory drugsGastrointestinal complicationsGI symptomsAnnual incidenceRisk stratificationGI riskRelative riskPrior historyEffective doseOlder ageA systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiology And Drug Safety 2006, 15: 213-220. PMID: 16456879, DOI: 10.1002/pds.1207.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsAlanine TransaminaseAnti-Inflammatory Agents, Non-SteroidalArchivesBenzophenonesBiomarkersBromobenzenesChemical and Drug Induced Liver InjuryHumansLiverPhenylacetatesPropionatesRandomized Controlled Trials as TopicUnited StatesUnited States Food and Drug AdministrationConceptsAcute liver failureNonsteroidal anti-inflammatory drugsSerious hepatotoxicityLiver failureRisk of ALFSystematic reviewDifferent nonsteroidal anti-inflammatory drugsCommon adverse eventsHepatic enzyme elevationFlu-like symptomsDrug-induced hepatotoxicityAnti-inflammatory drugsClinical trial dataSymptomatic hepatitisALT elevationElevated transaminasesAdverse eventsEnzyme elevationDrug withdrawalHepatocellular jaundiceRare caseMedWatch systemDrug AdministrationHepatotoxicityTrial data
2005
Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients
Rostom A, Goldkind L, Laine L. Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients. Clinical Gastroenterology And Hepatology 2005, 3: 489-498. PMID: 15880319, DOI: 10.1016/s1542-3565(04)00777-3.Peer-Reviewed Original ResearchConceptsLiver-related deathLiver-related hospitalizationsSerious adverse eventsAnti-inflammatory drugsAminotransferase elevationAdverse eventsSide effectsNonsteroidal anti-inflammatory drugsTrials of diclofenacHepatic side effectsProportion of patientsClinical side effectsRandomized Controlled TrialsBibliographic databases MEDLINEHigh rateArthritis patientsControlled TrialsRheumatoid arthritisHepatic toxicityInclusion criteriaDatabases MEDLINENSAIDsDrug AdministrationSystematic reviewToxicity outcomes
2004
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial
Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 2004, 127: 395-402. PMID: 15300570, DOI: 10.1053/j.gastro.2004.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDrug Therapy, CombinationFemaleGastric MucosaHumansIbuprofenIncidenceIsoenzymesLactonesMaleMembrane ProteinsMiddle AgedOsteoarthritisProstaglandin-Endoperoxide SynthasesRisk FactorsStomach UlcerSulfonesTablets, Enteric-CoatedConceptsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinCOX-2 selective inhibitorsDouble-blind trialUlcer incidenceNonselective NSAIDsLow-dose enteric-coated aspirinLow-dose aspirin usersCyclooxygenase-2 selective inhibitorSelective inhibitorNonsteroidal anti-inflammatory drugsEnteric-coated aspirinGastrointestinal mucosal injuryNumber of erosionsRisk of ulcerAnti-inflammatory drugsCOX-2 selective inhibitionYears of ageBaseline endoscopyAspirin usersDose aspirinErosive esophagitisCumulative incidenceMucosal injuryRepeat endoscopyUtilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis
Ofman JJ, Badamgarav E, Henning JM, Knight K, Laine L. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. The American Journal Of Medicine 2004, 116: 835-842. PMID: 15178499, DOI: 10.1016/j.amjmed.2004.02.028.Peer-Reviewed Original ResearchConceptsCOX-2 inhibitorsCardiac eventsHealth care costsGastrointestinal bleedingTraditional NSAIDsHigh riskGreater total health care costsNonsteroidal anti-inflammatory drug therapyCare costsAnti-inflammatory drug therapyCOX-2 inhibitor therapyTotal health care costsCyclooxygenase-2 selective inhibitorNonsteroidal anti-inflammatory drugsCardiac risk profileProton pump inhibitorsAnti-inflammatory drugsLogistic regression analysisNSAID therapyNSAID usersGastrointestinal riskInhibitor useNonselective NSAIDsInhibitor therapyCardiac riskProton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? Gastroenterological Disorders 2004, 4 Suppl 4: s33-41. PMID: 15580145.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI symptomsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinAnti-inflammatory drugsGI symptomsGI complicationsGI riskSide effectsDevelopment of NSAIDDaily proton pump inhibitor therapyHistamine-2 receptor antagonistsNSAID-induced gastric ulcersProton pump inhibitor therapyNSAID-induced ulcersGI side effectsUpper GI bleedingAnti-pyretic effectsGastrointestinal toxicityGI bleedingNSAID usersUlcer complicationsCardiovascular prophylaxisInhibitor therapyStandard doses
2002
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis
Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123: 1006-1012. PMID: 12360461, DOI: 10.1053/gast.2002.36013.Peer-Reviewed Original ResearchConceptsUpper GI eventsClinical upper GI eventsSelective cyclooxygenase-2 inhibitorHigh-risk patientsGI eventsRisk factorsCyclooxygenase-2 inhibitorClinical characteristicsRheumatoid arthritisClinical eventsNonsteroidal anti-inflammatory drugsClinical GI eventsRisk of NSAIDUpper GI complicationsLow-risk patientsSevere rheumatoid arthritisPatients' clinical characteristicsRheumatoid arthritis patientsAbsolute risk reductionLow-risk subgroupsAnti-inflammatory drugsIndividual risk factorsRisk of eventsGI complicationsNonselective NSAIDs
2001
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120: 594-606. PMID: 11179238, DOI: 10.1053/gast.2001.21907.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsGI eventsGI diseasePrevention of NSAIDAnti-inflammatory drug useClinical upper GI eventsHistory of ulcerUpper GI eventsHalf of patientsHigh-risk patientsAnti-inflammatory drugsGastrointestinal eventsNSAID doseGastroduodenal injuryNSAID usersClinical featuresGastric erosionsSteroid useCommon causeDrug usePatientsUlcersDiseaseRiskUnited States today
1995
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial
LAINE L, COMINELLI F, SLOANE R, CASINI‐RAGGI V, MARIN‐SORENSEN M, WEINSTEIN WM. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial. Alimentary Pharmacology & Therapeutics 1995, 9: 127-135. PMID: 7605852, DOI: 10.1111/j.1365-2036.1995.tb00361.x.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsH. pylori infectionNSAID ingestionProstaglandin E2 productionHistological injuryWeek 1H. pyloriGastroduodenal injuryPylori infectionNegative subjectsE2 productionWeek 4Prostaglandin productionH. pylori-associated gastritisDouble-blind trialNormal baseline endoscopyAnti-inflammatory drugsBaseline endoscopyChemical gastritisGastroduodenal damagePlacebo b.Gastrointestinal injuryNSAID useGastric histologyNSAID group